DIABETIC RETINOPATHY: FACTORS ASSOCIATED WITH PROGRESSION AND ADHERENCE TO SCREENING
Keywords:
diabetic retinopathy; screening; adherence; progression; teleophthalmology; artificial intelligence; blindness preventionAbstract
DOI: https://doi.org/10.46296/yc.v10i18.0882
Abstract
Diabetic retinopathy (DR) remains a leading cause of preventable visual impairment in adults with diabetes mellitus. Its clinical and public health relevance lies not only in the burden of disease but also in the fact that a significant proportion of cases with visual impairment can be prevented through intensive metabolic control, multifactorial management of cardiovascular risk, and early detection strategies. The objective of this narrative review was to synthesize recent evidence on factors associated with DR progression and adherence to screening, with an emphasis on high-impact publications and updated clinical guidelines. A narrative literature update was conducted, prioritizing international guidelines, systematic reviews, meta-analyses, and key studies available in high-impact biomedical journals. Particular emphasis was placed on recent documents related to screening, teleophthalmology, artificial intelligence, and clinical predictors of progression. Evidence shows that diabetic retinopathy (DR) progression is consistently associated with longer duration of diabetes, poor sustained glycemic control, hypertension, diabetic kidney disease, baseline retinopathy severity, and, in specific contexts, with rapid reductions in glycated hemoglobin (HbA1c). In contrast, adherence to screening depends on a complex network of individual, social, and healthcare system factors, including age, education level, income, insurance coverage, urban residence, health literacy, risk perception, history of eye disease, and service accessibility. The best-supported interventions include reminders, multicomponent approaches, teleophthalmology, fundus photography screening in primary care, and artificial intelligence algorithms. It is concluded that preventing blindness from DR requires integrating intensive clinical management with timely, accessible, and risk-centered screening models. In Latin American and resource-limited settings, combining primary care, remote retinal imaging, and outreach strategies can improve coverage and reduce inequities.
Keywords: diabetic retinopathy; screening; adherence; progression; teleophthalmology; artificial intelligence; blindness prevention.
Downloads
References
Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580-1591. doi:10.1016/j.ophtha.2021.04.027.
Owens DR, Gurudas S, Sivaprasad S, Zaidi F, Tapp R, Kazantzis D, et al. IDF Diabetes Atlas: a worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive. Diabetes Res Clin Pract. 2025;226:112346. doi:10.1016/j.diabres.2025.112346.
American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S252-S265. doi:10.2337/dc25-S012.
Lim JI, Kim SJ, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2025;132(4):P75-P162. doi:10.1016/j.ophtha.2024.12.020.
Perais J, Agarwal R, Evans JR, Loveman E, Colquitt JL, Owens D, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. Cochrane Database Syst Rev. 2023;2(2):CD013775. doi:10.1002/14651858.CD013775.pub2.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi:10.1056/NEJM199309303291401.
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122(11):1631-1640. doi:10.1001/archopht.122.11.1631.
Cardoso CRL, Leite NC, Dib E, Salles GF. Predictors of development and progression of retinopathy in patients with type 2 diabetes: importance of blood pressure parameters. Sci Rep. 2017;7(1):4867. doi:10.1038/s41598-017-05159-6.
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244. doi:10.1056/NEJMoa1001288.
Yamanouchi M, Mori M, Hoshino J, Kinowaki K, Fujii T, Ohashi K, et al. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of patients with type 2 diabetes and biopsy-proven diabetic kidney disease. BMJ Open Diabetes Res Care. 2019;7(1):e000726. doi:10.1136/bmjdrc-2019-000726.
Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21(3):454-466. doi:10.1111/dom.13538.
Simó R, Franch-Nadal J, Vlacho B, Real J, Amado E, Flores J, et al. Rapid reduction of HbA1c and early worsening of diabetic retinopathy: a real-world population-based study in subjects with type 2 diabetes. Diabetes Care. 2023;46(9):1633-1639. doi:10.2337/dc22-2521.
Rahmati M, Smith L, Boyer L, Fond G, Yon DK, Lee H, et al. Factors affecting global adherence for the uptake of diabetic retinopathy screening: a systematic review and meta-analysis. Am J Ophthalmol. 2024;268:94-107. doi:10.1016/j.ajo.2024.07.028.
Drinkwater JJ, Kalantary A, Turner AW. A systematic review of diabetic retinopathy screening intervals. Acta Ophthalmol. 2024;102(4):e473-e484. doi:10.1111/aos.15788.
Abou Taha A, Dinesen S, Vergmann AS, Grauslund J. Present and future screening programs for diabetic retinopathy: a narrative review. Int J Retina Vitreous. 2024;10:14. doi:10.1186/s40942-024-00534-8.
Lawrenson JG, Graham-Rowe E, Lorencatto F, Burr J, Bunce C, Francis JJ, et al. Interventions to increase attendance for diabetic retinopathy screening. Cochrane Database Syst Rev. 2018;1:CD012054. doi:10.1002/14651858.CD012054.pub2.
Weng CY, Maguire MG, Flaxel CJ, Jain N, Kim SJ, Patel S, et al. Effectiveness of conventional digital fundus photography-based teleretinal screening for diabetic retinopathy and diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(8):927-942. doi:10.1016/j.ophtha.2024.02.017.
Liu J, Gibson E, Ramchal S, Shankar V, Piggott K, Sychev Y, et al. Diabetic retinopathy screening with automated retinal image analysis in a primary care setting improves adherence to ophthalmic care. Ophthalmol Retina. 2021;5(1):71-77. doi:10.1016/j.oret.2020.06.016.
Ha SK, Gilbert JB, Le E, Ross C, Lorch A. Impact of teleretinal screening program on diabetic retinopathy screening compliance rates in community health centers: a quasi-experimental study. BMC Health Serv Res. 2025;25:318. doi:10.1186/s12913-025-12472-8.
Wolf RM, Channa R, Liu TYA, Zehra A, Bromberger L, Patel D, et al. Autonomous artificial intelligence increases screening and follow-up for diabetic retinopathy in youth: the ACCESS randomized control trial. Nat Commun. 2024;15(1):421. doi:10.1038/s41467-023-44676-z.
Published
How to Cite
License
Copyright (c) 2026 REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN - ISSN: 2697-3456

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


























